These investments represent positions where his stake exceeds 1%. A closer look at these holdings shows that seven stocks delivered negative returns, five of them have declined between 20% and 70% so far in calendar year 2025.
Wockhardt shares rocket 19% after FDA approval for antibiotic targeting drug-resistant infections. Check details
Wockhardt’s shares surged 19% after the U.S. FDA approved ZAYNICH, a novel intravenous antibiotic for complicated urinary tract infections. The drug, combining cefepime and zidebactam,